Eupraxia Pharmaceuticals
EPRX
35 hedge funds and large institutions have $104M invested in Eupraxia Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 6 closing their positions.
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
38% more capital invested
Capital invested by funds: $75.3M → $104M (+$28.9M)
30% more funds holding
Funds holding: 27 → 35 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8.32% less ownership
Funds ownership: 35.63% → 27.31% (-8.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.39M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.76M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$1.71M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.28M |
| 5 |
SC
SummitTX Capital
Fort Worth,
Texas
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$5.31M |
| 2 |
ABG
Ally Bridge Group
New York
|
-$3.19M |
| 3 |
BGC
Beutel, Goodman & Co
Toronto,
Ontario, Canada
|
-$2.15M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.48M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.43M |
EPRX Hedge Fund Activity: Q4 2025 in Review
35 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Eupraxia Pharmaceuticals (EPRX) for Q4 2025, worth a combined $104M — up 38% from $75.3M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new EPRX positions and 6 closed out — a net gain of 8 holders — while 8 added to existing stakes and 4 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.39M. The largest seller was Logos Global Management, exiting entirely with an estimated $5.31M sold.
- 35 institutional investors held Eupraxia Pharmaceuticals (EPRX) as of Q4 2025, up from 27 in Q3 2025.
- Funds reported $104M of Eupraxia Pharmaceuticals stock for Q4 2025, up 38% quarter-over-quarter.
- 14 funds opened new Eupraxia Pharmaceuticals positions in Q4 2025 and 6 closed out, a net change of +8 holders.
- The largest Eupraxia Pharmaceuticals buyer in Q4 2025 was Point72 Asset Management, an estimated $4.39M added.
- The largest Eupraxia Pharmaceuticals seller in Q4 2025 was Logos Global Management, an estimated $5.31M sold.
Based on aggregated 13F filings for Q4 2025.